Profound Medical Corp.PROF

時価総額

$2.3億

PER

切開不要の治療用組織アブレーション機器の新興企業。TULSA‑PROやSonalleveなどのプラットフォーム型アブレーションシステムを展開。2017年7月にSonalleve関連資産で買収、2019年10月にNASDAQ上場。カナダ本社を含む米国・欧州・中国を中心に展開。

	2020年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss for the year	-22	-29	-29	-28
Depreciation	-	-	-	1
Amortization of Intangible Assets	-	-	-	0
Non-cash lease expense adjustment	-	-	-	0
Share-based compensation (note 11)	-	-	-	3
Interest And Accretion Expense	-	-	-	1
Change in Amortized Cost of Trade And Other Receivable	-	-	-	-0
Trade and other receivables (note 3)	-	-	-	-0
Inventory (note 4)	-	-	-	-1
Prepaid expenses and deposits	-	-	-	-0
Increase (Decrease) in Accounts Payable and Accrued Liabilities	-	-	-	1
Deferred revenue	-	-	-	-1
Deferred tax liabilities (note 13)	-	-	-	-0
Deferred tax assets (note 13)	-	-	-	0
Net cash used in operating activities	-	-	-	-23
Issuance of commons shares (note 10)	-	-	-	62
Payments of financing costs (note 10)	-	-	-	5
Repayments of long-term debt (note 8)	-	-	-	3
Proceeds from Stock Options Exercised	-	-	-	0
Net cash provided by (used in) financing activities	-	-	-	55
Net increase (decrease) in cash and cash equivalents	-	-	-	31
Effect of exchange rate changes on cash	-	-	-	-3
Income Taxes Paid, Net	-	-	-	0